rVA576
Phase 2Small molecule
rVA576 is one of 43 small molecule programs targeting Bullous Pemphigoid. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
37 competitors in Bullous Pemphigoid
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsApproved
Rayos
RRoxane Laboratories
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Avlosulfon
AAlmirall, S.A.
Approved
Imuran
LLegacy Health System
Approved
Rituxan
RochePhase 3
Xolair
RochePhase 3
Fasenra
AstraZenecaPhase 3
Vyvgart
ArgenxPhase 3
Mabthera
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Paroxysmal Nocturnal Haemoglobinuria1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rVA576. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAKARI Therapeutics